 A ALIMENTARY TRACT AND METABOLISM
|
|
B BLOOD AND BLOOD FORMING ORGANS
|
|
C CARDIOVASCULAR SYSTEM
|
|
D DERMATOLOGICALS
|
|
G GENITO URINARY SYSTEM AND SEX HORMONES
|
|
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
|
|
J ANTIINFECTIVES FOR SYSTEMIC USE
|
|
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
|
L01 ANTINEOPLASTIC AGENTS
|
L01A ALKYLATING AGENTS
|
L01B ANTIMETABOLITES
|
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
|
L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
|
L01X OTHER ANTINEOPLASTIC AGENTS
|
L01XA Platinum compounds
|
L01XB Methylhydrazines
|
L01XC Monoclonal antibodies
|
L01XD Sensitizers used in photodynamic/radiation therapy
|
L01XE Protein kinase inhibitors
|
L01XE01 Imatinib [DG:DG00710]
|
L01XE02 Gefitinib
|
L01XE03 Erlotinib [DG:DG00711]
|
L01XE04 Sunitinib [DG:DG00712]
|
L01XE05 Sorafenib [DG:DG00713]
|
L01XE06 Dasatinib [DG:DG00714]
|
L01XE07 Lapatinib [DG:DG00715]
|
L01XE08 Nilotinib [DG:DG00716]
|
L01XE09 Temsirolimus
|
L01XE10 Everolimus
|
L01XE11 Pazopanib
|
L01XE12 Vandetanib
|
L01XE13 Afatinib [DG:DG00717]
|
L01XE14 Bosutinib [DG:DG00718]
|
L01XE15 Vemurafenib
|
L01XE16 Crizotinib
|
L01XE17 Axitinib
|
L01XE18 Ruxolitinib [DG:DG00719]
|
L01XE19 Ridaforolimus
|
L01XE21 Regorafenib [DG:DG00720]
|
L01XE22 Masitinib
|
L01XE23 Dabrafenib [DG:DG00721]
|
L01XE24 Ponatinib [DG:DG00722]
|
L01XE25 Trametinib [DG:DG00723]
|
L01XE26 Cabozantinib [DG:DG01670]
|
L01XE27 Ibrutinib
|
L01XE28 Ceritinib
|
L01XE29 Lenvatinib [DG:DG01362]
|
L01XE31 Nintedanib [DG:DG01374]
|
L01XE32 Cediranib [DG:DG01360]
|
L01XE33 Palbociclib [DG:DG01831]
|
L01XE34 Tivozanib [DG:DG01375]
|
L01XE35 Osimertinib
|
L01XE36 Alectinib [DG:DG01625]
|
L01XE37 Rociletinib
|
L01XE38 Cobimetinib [DG:DG01825]
|
L01XE39 Midostaurin
|
L01XE40 Olmutinib [DG:DG02916]
|
L01XE41 Binimetinib
|
L01XE42 Ribociclib [DG:DG02084]
|
L01XE43 Brigatinib
|
L01XE44 Lorlatinib
|
L01XE45 Neratinib [DG:DG02303]
|
 D08950 Neratinib (USAN/INN)
D10898 Neratinib maleate <US>
|
L01XE46 Encorafenib
|
L01XE47 Dacomitinib [DG:DG01793]
|
L01XE48 Icotinib [DG:DG01793]
|
L01XE50 Abemaciclib
|
L01XE51 Acalabrutinib [DG:DG03089]
|
L01XE52 Quizartinib [DG:DG01364]
|
L01XE53 Larotrectinib [DG:DG02923]
|
L01XE54 Gilteritinib [DG:DG01948]
|
L01XE56 Entrectinib
|
L01XE57 Fedratinib [DG:DG02968]
|
L01XX Other antineoplastic agents
|
L01XY Combinations of antineoplastic agents
|
L02 ENDOCRINE THERAPY
|
L03 IMMUNOSTIMULANTS
|
L04 IMMUNOSUPPRESSANTS
|
|
M MUSCULO-SKELETAL SYSTEM
|
|
N NERVOUS SYSTEM
|
|
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
|
|
R RESPIRATORY SYSTEM
|
|
S SENSORY ORGANS
|
|
V VARIOUS
|
Anatomical Therapeutic Chemical (ATC) Classification